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Abstract
Recent studies demonstrated that large amounts of the pro-
hormone peptide of brain natriuretic peptide (proBNP) can
be detected in plasma of healthy subjects and in particular
of patients with heart failure. As a result, a great part of
B-type natriuretic peptides measured in patients with cardio-
vascular disease may be devoid of biological activity. These
findings stimulated the set up of specific immunoassay
methods for the measurement of the intact proBNP peptide.
The aim of this review article is to discuss the methodolog-
ical characteristics and the possible clinical relevance of spe-
cific immunoassay methods for the measurement of the
proBNP peptide. From an analytical point of view, a fully
automated immunoassay of proBNP has some theoretical
advantages (e.g., a more stable molecule with higher molec-
ular weight than the derived peptides) compared to the active
hormone BNP. Recent studies supported the concept that the
precursor proBNP might be actually considered a circulating
prohormone, which can be cleaved by specific plasma pro-
teases in BNP, the active hormone, and NT-proBNP, an inac-
tive peptide. The peripheral processing of circulating
proBNP could likely be submitted to regulatory rules, which
might be impaired in patients with heart failure, opening new
perspectives in the treatment of heart failure (e.g., by study-
ing drugs inducing the cleavage of the prohormone into
active BNP). Furthermore, as a future perspective, the spe-
cific assay in the same plasma sample of the intact precursor
proBNP and of the biologically active peptide BNP, could
allow a more accurate estimation of the production/secretion
of B-type related peptides from cardiomyocytes and of the
global cardiac endocrine function.
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Introduction
Exactly 30 years ago, De Bold et al. (1) reported that intra-
venous injection of atrial extracts promotes a rapid and mas-
sive diuresis and natriuresis in rats, thus indicating that
unknown endogenous substances, produced by cardiomyo-
cytes, may have both diuretic and natriuretic properties. Only
a few years after, a family of natriuretic and vasodilator pep-
tides, named cardiac natriuretic hormones (CNHs), was iso-
lated, purified and then chemically identified in human
tissues (2, 3). CNHs now include atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP) and their related pep-
tides. Other natriuretic peptides, such as C-type natriuretic
peptide (CNP) and urodilatin are predominantly produced
and secreted by other tissues. In particular, CNP is produced
predominantly by endothelium, while urodilatin by renal
tubular cells by the same gene of ANP, and so this peptide
is present only in the urine (2, 3). All natriuretic peptides
share a direct diuretic, natriuretic and vasodilator effect and
an inhibitory and protective action on inflammatory process-
es of myocardium, endothelium and smooth muscle cells, in
this way modulating coagulation and fibrinolysis pathways,
and inhibiting platelet activation (2–7).
From a clinical point of view, CNHs gained interest espe-
cially when it was demonstrated that the measurement of
B-type-related natriuretic peptides (including BNP and NT-
proBNP) represents a significant improvement in the diag-
nostic and prognostic accuracy as well as a potential guide
to treatment in the clinical setting of heart failure (8–13).
For this reason, BNP/NT-proBNP assay is useful for diag-
nosis, risk stratification and follow-up of patients with heart
failure (HF) (8–14).
Recent studies reported that many B-type-related peptides
circulate in human blood (15–32). In particular, large
amounts of pro-hormone peptide (i.e., proBNP) can be
detected in plasma of patients with HF (15–22, 25, 32).
These data may indicate that the post-translational matura-
tion processing of BNP precursor is not efficient in heart
failure (3, 20, 23). As a result, a great part of B-type natri-
uretic peptides assayed in healthy subjects and patients with
cardiovascular disease may be devoid of biological activity.
These findings stimulated the set up of specific immunoassay
methods for the measurement of the intact proBNP peptide
(18, 19, 22, 24, 25). The aim of this review article is to
discuss the methodological characteristics and the possible
clinical relevance of specific immunoassay methods for the
measurement of the proBNP peptide.
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Biosynthesis of B-type natriuretic peptides
CNHs are synthesized by cardiomyocytes as pro-hormones
(i.e., proANP and proBNP), which are then split into two
fragments at the time of secretion from cardiomyocytes: the
longer fragment includes the NH2-terminus (NT-proANP and
NT-proBNP), while the shorter one (i.e., COOH-terminus
fragment) represents the active hormone (ANP and BNP).
In particular, human BNP is synthesized as a 134-amino
acid (aa) precursor protein (pre-proBNP) and is subsequently
processed to form a 108-aa propeptide, named proBNP. The
propetide hormones of the cardiac natriuretic peptides can be
enzymatically cleaved by proprotein convertases produced in
the cardiomyocytes, such as corin and furin (3). ProBNP is
then processed to form the 76-aa N-terminal peptide (i.e.,
NT-proBNP) and the biologically active 32-aa C-terminal
peptide (i.e., BNP1–32) (Figure 1). Some of the biosynthe-
sized pro-hormone (proBNP1–108) is O-glycosylated within
the Golgi apparatus (3, 28–31). If O-glycosylation does not
occur, proBNP1–108 can be cleaved to BNP77–108 and NT-
proBNP1–76 by the processing enzymes within the trans-
Golgi network. If O-glycosylation occurs, glycosylated-
proBNP1–108 cannot be cleaved, and uncleaved glycosylated
proBNP1–108 is secreted into the circulation. Finally, a small-
er part of intact pro-hormone is not glycosylated and cleaved,
and so this peptide can be present into circulation in intact
form as proBNP1–108. As indicated in the Figure 1, the gly-
cosylation on the threonyl residue in position 71 (Thr 71)
may regulate pro-hormone cleavage by either blocking or
guiding endoproteolytical enzymes (3, 31).
Circulating B-type-related peptides:
biochemical characteristics
According to the biosynthetic pathways described above, in
addition to the bioactive hormone BNP, a huge number of
circulating proBNP-derived fragments can be identified by
chromatographic procedures in plasma of experimental ani-
mals and patients with HF (3, 19, 20, 26, 27, 32). Moreover,
the proBNP1–108 and NT-proBNP1–76 (and probably also
other shorter peptides derived from these precursors) are
present in plasma in both glycosylated and non-glycosylated
form, especially in plasma samples of patients with heart
failure (3, 20, 29).
Some studies suggested that proBNP may be the major
BNP-immunoreactive form in human blood, especially in
patients with congestive heart failure (18–20, 32). In partic-
ular, Seferian et al. (29) recently reported that the plasma
pool of the endogenous NT-proBNP contains a small portion
(about 5%) of non-glycosylated or incompletely glycosylated
protein, and that this portion can be detected by antibodies
specific to the central part of the molecule.
A still open question is whether the circulating proBNP is
also present in polymer form, such as trimer (26, 27), or not
(20). Some more recent studies seem to indicate that the
high-molecular forms of proBNP, found in older studies,
were more probably due to the highly glycosylated forms of
the precursor peptide rather than to the polymerization forms
of the peptide (20).
It is usually assumed that the active peptide BNP1–32
should have a shorter plasma half-life and consequently low-
er plasma concentration, compared to proBNP1–108 and NT-
proBNP1–76 (Table 1) (2, 3, 16–18). However, there is no
study set up with the specific aim to accurately evaluate and
compare the respective plasma half-life of BNP, NT-proBNP
and proBNP in vivo in humans, but there are only a few
studies available in the literature, which use experimental
animal models. Using an experimental model in sheep, Pem-
berton et al. (33) reported that the plasma half-life of BNP
is about 4.8"1.0 min in vivo, while that of NT-proBNP was
69.6"10.8 min. Using an experimental rat model, Semenov
et al. (34) recently reported that the terminal half-life in vivo
for human glycosylated proBNP was 9.0"0.5 min compared
with 6.4"0.5 min for BNP. Moreover, the terminal half-life
was 15.7"1.4 min and 15.5"1.3 min for glycosylated and
non-glycosylated forms of NT-proBNP, respectively (34).
The proBNP assay: methodological
considerations
As hypothesized several years ago (35), but only recently
demonstrated (36), all immunoassays, which were considered
specific for BNP or NT-proBNP peptides, actually show
some cross-reactivity with proBNP. From an analytical point
of view, this finding points out an important methodological
problem: the need to set up more specific immunoassay
methods, not only for the biologically active peptide
BNP1–32, but also for all the other B-type related peptides,
including the precursor proBNP1–108.
Considering the proBNP assay, some different methodo-
logical approaches may be considered for the measurement
of the peptide (35). In plasma or tissue extracts, proBNP was
usually isolated by means of chromatographic procedures, in
particular by HPLC, and then identified and measured by
immunoassay or more accurately by mass spectrometry
(16–32, 35). These methods are highly specific for the pep-
tide, but also complex, time consuming and not available for
the clinical laboratory routine (35). To solve these problems,
at least three different methodological approaches were
developed with the aim to set up a highly specific immu-
noassay method for the measurement of proBNP (18, 24,
37).
Goetze et al. (24) set up a radioimmunoassay (RIA)
for proBNP assay based on the measurement of plasma
treated with trypsin, which cleaves all proBNP-related pep-
tides to the small 1–21 fragment. The aim of these authors
was to develop a processing-independent analysis (PIA) for
accurate quantification of proBNP and its fragments in plas-
ma. This method uses an antibody specific for a processing-
independent epitope of human proBNP. This antibody was
directed against the first 10 amino acids of proBNP peptide
and the same peptide, radio-iodinated with chloramines-T,
was used as a tracer in the RIA. Using this method, these
authors determined the total concentration of proBNP and its
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Figure 1 Schematic representation of biosynthesis, secretion and distribution of B-type related natriuretic peptides.
Some of the biosynthesized pro-hormone (proBNP-108) is O-glycosylated within the Golgi apparatus. If O-glycosylation does not occur,
proBNP-108 can be cleaved to BNP-32 and NT-proBNP-76 by the processing enzymes within the trans-Golgi network. If O-glycosylation
occurs, glycosylated-proBNP-108 cannot be cleaved, and uncleaved glycosylated proBNP-108 is secreted into the circulation. Finally, a
smaller part of intact pro-hormone is not glycosylated and cleaved, and so this peptide can be present into circulation in intact form as
proBNP-108. As indicated in the Figure, the glycosylation on the threonyl residue in position 71 (Thr 71) could regulate pro-hormone
cleavage by either blocking or guiding endoproteolytical enzymes wsee the reference (3) for more detailsx. Only BNP1–32, which is the active
hormone, is able to bind the specific receptors, NPR-A and NPR-C. NPR-A is a guanylate cyclase-coupled receptor, which mediates the
biological effects of cardiac natriuretic peptides. NPR-C, not coupled to a guanylate cyclase, has essentially a clearance function for all
natriuretic peptides wsee the reference (2) for more detailsx.
products in healthy volunteers and HF patients, showing that
proBNP values were greatly higher in patients (24). How-
ever, this RIA cannot be recommended for the clinical rou-
tine because this assay requires a preliminary treatment of
plasma samples with trypsin, a very long incubation time
(i.e., up to 5 days), and the use of radiolabeled material.
Furthermore, it is theoretically conceivable that this RIA
measures all the peptides containing the N-terminal part of
the precursor proBNP1–108, and so even the NT-proBNP. As
a consequence, for an accurate measurement of circulating
levels of the intact proBNP1–108 is also necessary to accu-
rately and independently assay the NT-proBNP concentra-
tion. From a pathophysiological point of view, it is important
to note that this RIA can allow an estimation of the overall
production by cardiomyocytes of the precursor proBNP,
including both the intact circulating proBNP1–108 and the part
of the precursor split before secretion (or in plasma) in
NT-proBNP (and BNP).
Tamm et al. (37) developed a sandwich immunofluores-
cence assay for the quantification of BNP and its precursor
proBNP. Authors reported that this immunofluorescence
assay recognizes with the same efficiency the BNP as well
as the recombinant glycosylated and non-glycosylated forms
of proBNP (37). This immunoassay method (named ‘‘single-
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Table 1 Biochemical and physiological characteristics of BNP, NT-proBNP and proBNP peptides.
BNP NT-proBNP proBNP
Molecular mass 3462 Da 8457 Daa 11900 Daa
Amino acids 32 76 108
Biological function Active hormone Inactive Pro-hormone
Plasma half life 15–20 min )60 min )60 min
Glycosylation Not glycosylated Highly glycosylated Highly glycosylated
In vitro stability Rapidly degraded in serum More stable More stable
Clearance mechanisms Clearance receptors and enzymatic degradation Enzymatic degradation Enzymatic degradation
aThe molecular mass (MM) of NT-proBNP and proBNP depends to the degree of glycosylation of the peptide; in the Table are reported
the MM of non-glycosylated peptides.
epitope sandwich assay’’) is different from the conventional
sandwich assay since it requires only one epitope for antigen
immunodetection by two different monoclonal antibodies. In
this novel immunoassay, the first antibody is used as a cap-
ture antibody and is specific for the region consisting of BNP
amino acid residues 11–22, which is the most stable part of
the peptide and includes the biologically active cysteine ring.
The second antibody is used as a detection antibody and
recognizes the immune complex, including the antigen (i.e.,
BNP11–22) bound to the first antibody. In other words, the
second antibody does not recognize the free antigen, but the
primary immune complex, consisting of the first antibody
and BNP, operates as antigen for the second antibody. It is
also important to note that this immunoassay method is not
theoretically specific for the intact proBNP1–108 peptide.
Indeed, the single-epitope sandwich assay should also rec-
ognize all the peptides (shorter than proBNP), which include
the region consisting of amino acid residues 11–22 of BNP
and are also able to form a complex with the first antibody.
Giuliani et al. (18) selected a specific monoclonal antibody
(named ‘‘mAb Hinge76’’) that recognizes the cleavage site
of proBNP1–108, an epitope found only in the precursor form
(see Figure 1). This monoclonal antibody recognizes the
recombinant proBNP1–108 in a dose-dependent manner, with-
out any significant cross-reactivity with either recombinant
NT-proBNP1–76 or synthetic BNP1–32. These authors set up
a sandwich immunoassay for the measurement of proBNP,
by combining the monoclonal antibody mAb Hinge76 with
a polyclonal antibody directed against BNP1–32. An auto-
mated version of this method on the BioPlex 2200 analyzer
was then set up and their analytical characteristics were eval-
uated (38). More recently, some studies reported the clinical
results obtained in general community (25) and in patients
with heart failure (39) or chronic renal disease (40) by meas-
uring proBNP concentrations with of this immunoassay
method.
Should we need the proBNP assay?
From an analytical point of view, a fully automated immu-
noassay of proBNP has some theoretical advantages as bio-
marker (i.e., more stable molecule, higher molecular weight,
lower biological variability) compared to the measurement
of the active hormone BNP (Table 1). As a future perspec-
tive, the simultaneous measurement in the same plasma sam-
ple with two methods, one specific for the intact precursor
proBNP1–108, and the other for active peptide BNP1–32, could
allow a more accurate estimation of both production/secre-
tion of B-type related peptides from cardiomyocytes and
overall activity of the cardiac endocrine function, compared
to the single assay of either peptide (41). Information
obtained by contemporaneous measurement of proBNP and
BNP with specific assays should likely extend our present
understanding of pathophysiological mechanisms linking
together disease progression and cardiac endocrine dysfunc-
tion. Indeed, a recent study in ambulatory patients with
chronic systolic HF showed that the combined assessment of
conventional BNP and proBNP immunoassays provides
additional information in determining the risk of adverse
clinical outcomes, particularly in patients with low BNP
values (22). However, designed studies will be necessary in
order to estimate and compare the diagnostic and prognostic
accuracy of specific assays for different B-type related pep-
tides: BNP, NT-proBNP and intact proBNP, used either alone
or in combination.
From a pathophysiological point of view, a blunted natri-
uretic response after pharmacological doses of ANP and
BNP has been observed in experimental models and in
patients with chronic heart failure, suggesting a resistance to
the biological effects of CNH, principally to natriuresis (2,
42, 43). As discussed in detail previously (2), resistance to
the biological action of CNH can be attributed at least to
three kinds of different causes/mechanisms, acting at pre-
receptor, receptor and post-receptor level, respectively.
Considering the possible causes of resistance at the pre-
receptor level, recent findings (16–32, 34, 44, 45) suggest
that in patients with heart failure there may be an insufficient
post-translation maturation of the biosynthetic precursors of
B-type natriuretic peptide system. According to these find-
ings (16–32, 34, 44, 45), it is theoretically conceivable that
the active hormone (i.e., BNP) may be produced even in vivo
from the circulating precursor proBNP1–108 by plasma
enzyme degradation. Indeed, the soluble form of corin, a
transmembrane serine protease able to cleave proBNP, is also
capable of processing the circulating intact precursor of
natriuretic hormones (44). Dong et al. (45) recently
confirmed that soluble corin is measurable in human blood.
Furthermore, these authors reported that plasma corin levels
are significantly lower in heart failure patients than in healthy
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controls and that the reduction in plasma enzyme is corre-
lated to the severity of the disease (45). Finally, Semenov et
al. demonstrate that synthetic or recombinant human proBNP
can be processed to active BNP in the circulating blood,
when injected in the femoral vein of rats (34).
The above-mentioned studies (16–32, 34, 44, 45) open a
new and more complex scenario regarding the B-type natri-
uretic peptides, the precursor proBNP actually acting as a
circulating pro-hormone. The peripheral processing of cir-
culating proBNP could likely be submitted to regulatory
rules, which might be impaired in patients with heart failure,
opening new perspectives in the treatment of heart failure.
A novel pharmacological target may be pharmacodynamic
actions of drugs inducing and/or modulating the maturation
of the prohormone into active hormone (i.e., BNP). However,
further studies are necessary to demonstrate whether proBNP
may be an equivalent alternative to BNP/NT-proBNP assay
or may add incremental value to these existing biomarkers
of cardiac dysfunction.
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